Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Matthew S. Najor"'
Autor:
Molly DiScala, Matthew S Najor, Timothy Yung, Deri Morgan, Abde M Abukhdeir, Melody A Cobleigh
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance remains a major hurdle in the clinical management of these patients. Therefore, identifying
Externí odkaz:
https://doaj.org/article/53bcf4b5a1294ff8a62f60026c5f7c46
Autor:
Liam Portt, Melody A. Cobleigh, Sanja Turturro, Matthew S. Najor, Satnam Brar, Abde M. Abukhdeir, Timothy Yung
Publikováno v:
Cancer Research. 81:PS18-30
Background: The Ras signaling pathway is a key oncogenic growth signaling pathway. The neurofibromatosis gene (NF1) is a tumor suppressor gene and negative regulator of Ras. Approximately 20% of breast cancers experience loss of active NF1 protein, l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16fe5a357eaae6aec9f69ad5087a6a17
https://doi.org/10.1158/1538-7445.sabcs20-ps18-30
https://doi.org/10.1158/1538-7445.sabcs20-ps18-30
Autor:
Liam Portt, Melody A. Cobleigh, Timothy Yung, Matthew S. Najor, Abde M. Abukhdeir, Sanja Turturro, Christopher S. Malarkey
Publikováno v:
Breast Cancer Research and Treatment. 177:325-333
The PI3K pathway, which includes the PI3K catalytic subunits p110α (PIK3CA) and the PI3K regulatory subunit p85α (PIK3R1), is the most frequently altered pathway in cancer. We encountered a breast cancer patient whose tumor contained a somatic alte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b2815fcd20ba30ab9171fe0b0380472
https://doi.org/10.1007/s10549-019-05320-x
https://doi.org/10.1007/s10549-019-05320-x
Autor:
Duarte Mota de Freitas, Brian D. Leverson, Saad Kothawala, Kenneth W. Olsen, Matthew S. Najor, Jesse Goossens
Publikováno v:
ACS Omega, Vol 3, Iss 10, Pp 12320-12329 (2018)
ACS Omega
ACS Omega
G-proteins play a central role in signal transduction by fluctuating between “on” and “off” phases that are determined by a conformational change. cAMP is a secondary messenger whose formation is inhibited or stimulated by activated Giα1 or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c759d92442afe42c4a133dcff82180d
https://doaj.org/article/3d750957dd86447b81e059d804e60807
https://doaj.org/article/3d750957dd86447b81e059d804e60807
Autor:
Liannian Liu, Denise M. Scholtens, David Ivancic, Jun Wang, Vamsi Parimi, Matthew S. Najor, Manish Ranjan, Abde M. Abukhdeir, Megan E. Sullivan, Mi Ran Choi, Ali Shidfar, Demirkan B. Gursel, Seema A. Khan
Publikováno v:
International Journal of Cancer. 140:2484-2497
Risk biomarkers for estrogen receptor (ER)-negative breast cancer have clear value for breast cancer prevention. We previously reported a set of lipid metabolism (LiMe) genes with high expression in the contralateral unaffected breasts (CUBs) of ER-n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e90cd7d5fe14faba72167971f1c4292a
https://doi.org/10.1002/ijc.30680
https://doi.org/10.1002/ijc.30680
Autor:
Sanja B, Turturro, Matthew S, Najor, Timothy, Yung, Liam, Portt, Christopher S, Malarkey, Abde M, Abukhdeir, Melody A, Cobleigh
Publikováno v:
Breast cancer research and treatment. 177(2)
The PI3K pathway, which includes the PI3K catalytic subunits p110α (PIK3CA) and the PI3K regulatory subunit p85α (PIK3R1), is the most frequently altered pathway in cancer. We encountered a breast cancer patient whose tumor contained a somatic alte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::93b97457d6a0cccf860c6202250dbc8a
https://pubmed.ncbi.nlm.nih.gov/31209687
https://pubmed.ncbi.nlm.nih.gov/31209687
Autor:
Timothy Yung, Melody A. Cobleigh, Abde M. Abukhdeir, Deri Morgan, Molly DiScala, Matthew S. Najor
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234146 (2020)
Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance remains a major hurdle in the clinical management of these patients. Therefore, identifying
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1ae28856a4595c9acd4b2541491547
https://doi.org/10.1371/journal.pone.0234146
https://doi.org/10.1371/journal.pone.0234146
Publikováno v:
Journal of Clinical Oncology. 38:e13006-e13006
e13006 Background: Approximately 20% of breast cancers are HER2-positive. Trastuzumab has improved patient outcomes significantly for these cancers. However, acquired resistance occurs in almost all patients with metastatic breast cancer. Therefore,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a274bf866e93b6668580e3cf40351d95
https://doi.org/10.1200/jco.2020.38.15_suppl.e13006
https://doi.org/10.1200/jco.2020.38.15_suppl.e13006
Autor:
Nailliw Z. Preite, Abde M. Abukhdeir, Mahboobeh Mahdavinia, Usman Barlass, Matthew S. Najor, Janet P. Zayas, Ali Keshavarzian, Lijuan Zhang, Brandon B. Shetuni, Faraz Bishehsari, Sanja Turturro
Pancreatic ductal adenocarcinoma (PDA) is characterized by epithelial mutations in KRAS and prominent tumor-associated inflammation, including macrophage infiltration. But knowledge of early interactions between neoplastic epithelium and macrophages
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::783b3c22f224a6cc50b1a379de3cfbbc
https://europepmc.org/articles/PMC6128758/
https://europepmc.org/articles/PMC6128758/
Publikováno v:
Protein Science. 23:1392-1402
Giα1 is the inhibitory G-protein that, upon activation, reduces the activity of adenylyl cyclase. Comparison of the crystal structures of Giα1 bound to GDP•AMF or GTPγS with that of the inactive, GPD-bound protein indicates that a conformational
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09498bd6f0a0d32d0a4a11c2990647dd
https://doi.org/10.1002/pro.2523
https://doi.org/10.1002/pro.2523